Figure 3
From: Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent
Competition for Hsp90 binding to the TPR2A domain of Hop. Hsp90 (1 μM) was passed over immobilized TPR2A domain of human Hop (5000 resonance units [RU]) in the absence or presence on increasing concentrations of TPR (A) or TPR scramble (B) peptide (1.4, 14, 140, 280, and 700 μM, and 1 mM). The SPR signal in the absence of competing peptides was used as a reference (100% binding). (C) Equilibrium response levels obtained in the presence of competing peptides - TPR (KAYARIGNSYFK), TPR scramble (RKFSAAIGYNKY), TPR mutant 1 (KAYAAAGNSYFK), or TPR mutant 2 (KAYARIGNSGGG) - were normalized and plotted against the peptide concentrations as described in the Materials and Methods section.